Acrocephalosyndactylia clinical trials
The registry lists 33 studies for Acrocephalosyndactylia across more than 10 countries. 6 are recruiting or about to start. 6 of them are mainly about Acrocephalosyndactylia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Acrocephalosyndactylia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Incyte Corporation (7) · Janssen Research & Development, LLC (3) · Basilea Pharmaceutica (2) · Teresa Helsten, MD (2) · Eisai Co., Ltd. (2) · M.D. Anderson Cancer Center (1) · National Taiwan University Hospital (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)
What is being tested here
Drugs under test in Acrocephalosyndactylia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| E-7090 | 1 | 0 | 3 |
| Futibatinib | 1 | 1 | 1 |
| Zimberelimab | 1 | 1 | 1 |
| Pemigatinib | 0 | 0 | 6 |
| Erdafitinib | 0 | 0 | 3 |
| Infigratinib | 0 | 0 | 3 |
| Derazantinib | 0 | 0 | 2 |
| Rogaratinib | 0 | 0 | 2 |
| Alpelisib | 0 | 0 | 1 |
| Pembrolizumab | 0 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Jan 2027A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 · Kidney Cancer Research Bureau
- Mar 2027Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations · Tyra Biosciences, Inc
- Apr 2027ASO Treatment for Syndromic Craniosynostoses · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who these studies take
Of the 5 Acrocephalosyndactylia studies recruiting now, 4 (80%) set no upper age limit and 1 (20%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (60%) | 3 (60%) |
| 30 | 4 (80%) | 4 (80%) |
| 40 | 4 (80%) | 4 (80%) |
| 50 | 4 (80%) | 4 (80%) |
| 65 | 4 (80%) | 4 (80%) |
| 75 | 4 (80%) | 4 (80%) |
| 85 | 4 (80%) | 4 (80%) |
Across all 33 studies, recruiting or not: 9% stop at 75 or younger and 6% at 65; 9% take children; 3% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 33 of 33. search them.
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1RecruitingNCT07292168Phase 1/21 country
- ASO Treatment for Syndromic CraniosynostosesRecruitingNCT075353721 country
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 34 countries
- NCCH2006/MK010 Trial (FORTUNE Trial)RecruitingNCT04962867Phase 21 country
- Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress SyndromeNot yet recruitingNCT06322758Not applicable
- GROWing Up With Rare GENEtic SyndromesRecruitingNCT044633161 country
- A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerCompletedNCT05567185Phase 11 country
- Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsActive, not recruitingNCT06160752Phase 11 country
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 11 country
- A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCompletedNCT04238715Phase 22 countries
- Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 216 countries
- Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)TerminatedNCT03822117Phase 211 countries
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 12 countries
- Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)CompletedNCT02924376Phase 212 countries
- A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)CompletedNCT02872714Phase 211 countries
- Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationCompletedNCT05253807Phase 25 countries
- A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 23 countries
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01703481Phase 13 countries
- Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/215 countries
- Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/214 countries
- A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene AberrationsCompletedNCT0395591314 countries
- Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedNCT03762122Phase 21 country
- Phase I BLASST-3 TrialWithdrawnNCT04972253Phase 1
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Phase 21 country
- Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedNCT04125693Phase 21 country
- Phase 1b Trial of BGJ398/BYL719 in Solid TumorsCompletedNCT01928459Phase 112 countries
- Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGFTerminatedNCT01367275Phase 21 country
- A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)CompletedNCT03235570Phase 11 country
- Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial DifferencesCompletedNCT003409641 country
- Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR SignalingWithdrawnNCT02846766Phase 21 country
- Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway AberrationsWithdrawnNCT02747797Phase 21 country
- TWIST Human Gene and Cleft Lips and PalatesTerminatedNCT00213889Not applicable1 country
- Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.Status unknownNCT019273541 country